The global BPH treatment market is expected to grow from USD 33,031.10 million in 2024 to USD 47,045.80 million by 2034, at a ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

The most common adverse reactions with treatment were headache ... men with unresolved symptoms of OAB while being treated for BPH, which underscores our urgency to deliver for those affected ...

Several conditions can lead to urinary flow problems. In men, prostate changes often affect urination patterns, particularly ...

We are excited to reach this important milestone in the Expander-2 Pivotal Trial,” said Paul Edwards, President and CEO of Prodeon Medical. “Completing enrollment is a key step in our mission to ...

A new research has revealed that drugs used to treat enlarged prostate symptoms may protect against a common form of dementia. Meaning, men on terazosin, doxazosin, and alfuzosin were 40 per cent ...

Winter leads to an increased risk of problems related to the prostate gland in seniors. Cold weather causes urinary and ...

The drop in temperature during winter can tighten the pelvic organ reducing the blood flow ( vasoconstriction). This can ...